drugset / Trial / NCT00546455

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

NCT00546455

Phase 2 Suspended 21 enrolled University of California, San Diego
RandomizedParallel-groupTriple-blindTreatment

Summary

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.

Timeline

Start
2007-12
Primary completion
2012-01
Completion
2099-01

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule 200 mg

Indications